2023
2023
Leading Mirae Asset Financial Group's ($600bn AUM) first U.S.-based venture capital firm dedicated to investing in life science companies
2020 - 2023
2020 - 2023
Helped to lead minority equity investments in healthcare across genetic disease/gene therapy, cell therapy, regenerative medicine, oncology, autoimmune disease/inflammation, CNS/mental health, and digital health
2022 - 2023
2022 - 2023
Deep understanding of protein homeostasis and ubiquitin biology to effect protein modulation (e.g. degradation) beginning in CNS.
2021 - 2023
2021 - 2023
Leveraging the gut-brain-immune axis to deliver live biotherapeutic products in CNS indications (Epilepsy, ALS)
2021 - 2023
2021 - 2023
AI-driven chat bot utilizing validated psychiatry/psychology principles (CBT, DBT, IPT) to deliver prescription and non-prescription digital therapeutics for mental health.
2021 - 2023
2021 - 2023
One of the world's leading health symptom assessment apps revolutionizing the digital healthcare journey for patients.
2021 - 2022
2021 - 2022
Revolutionizing the manufacturing for iPSC-derived cell therapies
2021 - 2022
2021 - 2022
Developing the first biomarker for systemic chronic inflammation using serum-derived immunological proteins leveraging the data from a 10-year longitudinal study from Stanford (1KIP).
2021 - 2022
2021 - 2022
Genetic engineering of skin microbes to treat dermatologic conditions with a lead program in Netherton Syndrome. IND for Netherton syndrome cleared by FDA at the end of 2022, IPO in H1 2023 (NYSE: AZTR).